Martin Marietta (MLM) recently had their rating decreased from Buy to Neutral. Longbow is the brokerage firm which is currently analyzing this company and found it necessary to change their rating. This is usually a bearish sign for the stock, and this brokerage house may tell its clients to sell the stock. The share prices may fall because of this action. Analysts believe that the company's share price may begin to fall. Shares of MLM fell by 5.07% or $-3.84/share to $71.92. In the past year, the shares have traded as low as $59.93 and as high as $95.00. On average, 453308 shares of MLM exchange hands on a given day and today's volume is recorded at 271478.
Healthways (HWAY) recently had their rating changed from Hold to Buy. Stifel Nicolaus is the brokerage firm which is currently analyzing this company and found it necessary to change their rating. This is usually a bullish sign for the company's share price, as these brokerages begin to tell their clients to start buying the upgraded stock. The shares may see a continued uptrend because of this. Analysts believe that the company's share price may begin to improve. The target price is currently set at $13 per share by the brokerage firm. Shares of HWAY traded higher by 7.55% or $0.49/share to $6.98. In the past year, the shares have traded as low as $5.59 and as high as $17.62. On average, 352623 shares of HWAY exchange hands on a given day and today's volume is recorded at 406088.
THQ Inc (THQI) is currently being analyzed by the brokerage firm Brean Murray. They have just decreased their rating from Buy to Hold. This indicates that the company may not be doing as well as investors were expecting. Look for potential selling pressure or a downside move in the share price. Shares of THQI fell by 33.57% or $-0.4901/share to $0.97. In the past year, the shares have traded as low as $1.37 and as high as $6.53. On average, 1099740 shares of THQI exchange hands on a given day and today's volume is recorded at 11409102.
WBB Securities, the brokerage firm, has recently decreased the rating on Jazz Pharma (JAZZ). They lowered the rating from Buy to Hold. The brokerage firm believes the company is on the downswing and there could be potential savings or capital preservation in selling the stock now. The target price is currently set at $40 per share by the brokerage firm. Shares of JAZZ fell by 4.21% or $-1.64/share to $37.32. In the past year, the shares have traded as low as $17.48 and as high as $47.88. On average, 820436 shares of JAZZ exchange hands on a given day and today's volume is recorded at 385400.
